136 related articles for article (PubMed ID: 38192162)
1. Clinical factor-based risk stratification for precision therapy in locally advanced squamous cell carcinoma of the uterine cervix.
Liu FY; Chen WC; Pan YB; Wang CC; Tang YH; Chou HH; Chao A; Yang LY; Lai CH
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38192162
[TBL] [Abstract][Full Text] [Related]
2. Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial.
Liu FY; Lai CH; Yang LY; Wang CC; Lin G; Chang CJ; Chang WY; Huang SH; Huang YE; Peng NJ; Hong JH; Chao A; Chou HH; Chang YC; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1812-23. PubMed ID: 27160224
[TBL] [Abstract][Full Text] [Related]
3. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
[TBL] [Abstract][Full Text] [Related]
4. Metabolic parameters with different thresholds for evaluating tumor recurrence and their correlations with hematological parameters in locally advanced squamous cell cervical carcinoma: an observational
Du S; Sun H; Gao S; Xin J; Lu Z
Quant Imaging Med Surg; 2019 Mar; 9(3):440-452. PubMed ID: 31032191
[TBL] [Abstract][Full Text] [Related]
5. Tumour and pelvic lymph node metabolic activity on FDG-PET/CT to stratify patients for para-aortic surgical staging in locally advanced cervical cancer.
Martinez A; Voglimacci M; Lusque A; Ducassou A; Gladieff L; Dupuis N; Angeles MA; Martinez C; Tanguy Le Gac Y; Chantalat E; Hitzel A; Courbon F; Ferron G; Gabiache E
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1252-1260. PubMed ID: 31915897
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Sum of Metabolic Tumor Volume of Primary Tumor and Lymph Nodes Using 18F-FDG PET/CT in Patients With Cervical Cancer.
Hong JH; Min KJ; Lee JK; So KA; Jung US; Kim S; Eo JS
Medicine (Baltimore); 2016 Mar; 95(9):e2992. PubMed ID: 26945420
[TBL] [Abstract][Full Text] [Related]
8. Roles of posttherapy
Liu FY; Su TP; Wang CC; Chao A; Chou HH; Chang YC; Yen TC; Lai CH
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1197-1204. PubMed ID: 29470614
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer.
Yilmaz B; Dağ S; Ergul N; Çermik TF
Nucl Med Commun; 2019 Mar; 40(3):219-227. PubMed ID: 30585896
[TBL] [Abstract][Full Text] [Related]
11. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?
Akkas BE; Demirel BB; Dizman A; Vural GU
Ann Nucl Med; 2013 Oct; 27(8):756-63. PubMed ID: 23793926
[TBL] [Abstract][Full Text] [Related]
12. Standardized uptake value and metabolic tumor volume measured by ¹⁸F FDG PET/CT are sensitive biomarkers for the presence of lymph node metastasis in patients with cervical carcinoma.
Vural GU; Akkas BE; Demirel BB
Rev Esp Med Nucl Imagen Mol; 2014; 33(5):268-73. PubMed ID: 25018135
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix.
Huang EY; Huang YJ; Chanchien CC; Lin H; Wang CJ; Sun LM; Tseng CW; Tsai CC; Ou YC; Fu HC; Chen HC; Hsu HC; Wang CY
Radiat Oncol; 2012 Jan; 7():13. PubMed ID: 22289572
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activity determines survival depending on the level of lymph node involvement in cervical cancer.
Martinez A; Chantalat E; Angeles MA; Ferron G; Ducassou A; Daix M; Attal J; Bétrian S; Lusque A; Gabiache E
BMC Cancer; 2022 Jul; 22(1):810. PubMed ID: 35870900
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemoradiotherapy.
Chong GO; Jeong SY; Park SH; Lee YH; Lee SW; Hong DG; Kim JC; Lee YS; Cho YL
PLoS One; 2015; 10(9):e0137743. PubMed ID: 26368542
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Volume-Based Metabolic Parameters Obtained by 18F-FDG-PET/CT in Patients With Locally Advanced Squamous Cell Cervical Carcinoma.
Liang Y; Li X; Wan H; Fang Y; Zheng R; Zhang W; Liu Y; Chen C; Wu N
J Comput Assist Tomogr; 2018; 42(3):429-434. PubMed ID: 29369948
[TBL] [Abstract][Full Text] [Related]
17. (
Scher N; Castelli J; Depeursinge A; Bourhis J; Prior JO; Herrera FG; Ozsahin M
Cancer Radiother; 2018 May; 22(3):229-235. PubMed ID: 29650390
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of primary tumor and lymph node volumetric metabolic parameters at pre-treatment F-18 FDG PET/CT in nasopharyngeal carcinoma.
Demirel BB; Gülbahar Ateş S; Atasever Akkaş E; Göksel F; Uçmak G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(6):367-373. PubMed ID: 37391092
[TBL] [Abstract][Full Text] [Related]
19. Enhancing prognosis prediction using pre-treatment nodal SUVmax and HPV status in cervical squamous cell carcinoma.
Hong CM; Park SH; Chong GO; Lee YH; Jeong JH; Lee SW; Lee J; Ahn BC; Jeong SY
Cancer Imaging; 2019 Jun; 19(1):43. PubMed ID: 31234933
[TBL] [Abstract][Full Text] [Related]
20.
Leray H; Gabiache E; Courbon F; Brenot-Rossi I; Colineaux H; Lepage B; Lambaudie E; Martinez A; Voglimacci M; Weyl A; Deslandres M; Ducassou A; Motton S; Vaysse C; Chantalat E
J Nucl Med; 2020 Oct; 61(10):1442-1447. PubMed ID: 32034109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
